Scottish sensor technology Novosound has secured a patent for its ultrasonic instrumentation system, with the company recently launching its related Slanj platform targeted at the medical and wearable device sectors worldwide. The new ultrasound imaging patent underpins Novosound’s first-mover advantage to initiate efforts in consumer health, including blood pressure monitoring for smartwatches.
Â
The announcement marks Novosound’s 21st patent awarded since 2018, and gives the company the exclusive rights to sell the technology that has underpinned leading research in Scotland and the United States into wireless, wearable ultrasound. “Alongside our commercial and R&D partners, we have been able to push the boundaries of innovation around ultrasound technology, what we describe as ultrasound, integrated, everywhere,” says Novosound CEO and Co-founder Dave Hughes.
“I’m really proud that Novosound has obtained the first patent for a wearable ultrasound system. This allows us to integrate and license the technology with smartwatch partners, looking deeper into the body and enhancing the measurements their optical and electrical sensors provide, opening up the holy grail of 24/7 blood pressure monitoring on the wrist,” he adds.
Novosound is also progressing patent applications for its wearable technology worldwide, while ongoing research and pilot projects are continuing with global tech giants, including around muscle activity and blood pressure monitoring in smartwatches, and with institutions like the Texas Medical Centre.
Â
“This technology builds on the legacy of ultrasound in Scotland, where it was first demonstrated as a medical diagnostic technique at the University of Glasgow in 1954, and now as a Scottish company moves it out of the hospital and into the home via a wearable device,” Dave Hughes concludes.
Novosound is forecasting its fourth year in a row of annual revenue growth, powered by strong growth in North American markets, where the company is active in the medical and industrial markets. The company, which was the University of the West of Scotland’s first ever spinout in 2018, has raised over £10 million since it appointed former Intel executive David Jolliffe as CFO in 2023, while also announcing commercial contracts with Nasdaq-listed PAVmed Inc., and partnerships that strengthen its position in fast-growing digital health markets.
At the heart of Novosound’s technology lies a successful effort to scale down traditional ultrasound components, integrating them into user-friendly, wearable formats. This breakthrough allows for real-time monitoring of various health conditions, including 24/7 blood pressure monitoring, heart rate and performance, dehydration, muscle loading and recovery and other vital signs, without the need for bulky, stationary equipment.
www.novosound.net
Source link
